@article{TLCR116522,
author = {Hilal Ozakinci and Bina Desai and Denise Kalos and Dung-Tsa Chen and Menkara Henry and Hitendra Solanki and Theresa A. Boyle and Humberto E. Trejo Bittar and Gina S. Nazario and Eric B. Haura and Andriy Marusyk and Bruna Pellini},
title = {Pre-clinical efficacy of trastuzumab deruxtecan plus sotorasib in KRASG12C-mutant non-small cell lung cancer and exploratory HER2 profiling in human tumors},
journal = {Translational Lung Cancer Research},
volume = {15},
number = {4},
year = {2026},
keywords = {},
abstract = { KRASG12C inhibitors such as adagrasib and sotorasib have shown promise in treating KRASG12C-mutant non-small cell lung cancer (NSCLC), but treatment resistance remains a major challenge. In this study, we investigated the therapeutic potential of combining trastuzumab deruxtecan (T-DXd), an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC), with sotorasib in KRASG12C-mutant NSCLC xenografts and evaluated HER2 expression in NSCLC patient samples.},
issn = {2226-4477}, url = {https://tlcr.amegroups.org/article/view/116522}
}